What are the fundraising trends in the Brain-Computer interface market?
In our updated market reports, you will find everything you need
SUMMARY
We analyzed publicly disclosed equity rounds raised by pure-play brain-computer interface companies across full-year 2024, full-year 2025, and year-to-date 2026 through July 2026. The tracker only includes disclosed equity rounds of $300K or more and keeps companies whose activity is more than 80% focused on recording, interpreting, stimulating, or interfacing with neural signals to control devices, restore function, support neuroprosthetics, enable rehabilitation, or advance clinical neurotechnology.
The brain-computer interface market has expanded sharply by capital. Disclosed funding rose from about $406M in 2024 to about $1.0B in 2025, and then reached about $933M in the first half of 2026. That makes the recent funding signal much larger than the 2024 baseline, but the headline totals are heavily shaped by a few large rounds.
Deal count tells a more cautious story. Full-year 2024 and full-year 2025 each had 9 disclosed qualifying deals, while year-to-date 2026 had 10. The market is not exploding because dozens of new companies are raising; it is expanding because a small number of companies are attracting much larger checks.
Capital concentration is the defining feature of the brain-computer interface market. In 2025, Neuralink’s $650M round represented about 65% of all disclosed capital. In year-to-date 2026, BrainCo, Merge Labs, and Science Corporation together represented about 82% of disclosed capital.
The brain-computer interface market is still winner-takes-most. The bottom half of deals captured only about 5% of capital in 2024, about 5% in 2025, and about 4% in year-to-date 2026. Bigger totals have not translated into a healthier lower half of the market.
The category mix is changing. Implantable BCIs dominated 2025 with about 92.5% of disclosed capital, but year-to-date 2026 broadened across Rehabilitation Interfaces, Non Invasive BCIs, Clinical Neurotechnology, Implantable BCIs, and Neuroprosthetics. The market is still concentrated by company, but it is becoming more diverse by technical architecture.
Late-stage and follow-on rounds remain the main home for large checks. In 2025, Series B and later rounds captured nearly 90% of capital. Year-to-date 2026 looked more balanced, with early-stage and Series A rounds capturing about 37%, but that figure was strongly inflated by Merge Labs’ $250M seed round.
New startups are still entering the brain-computer interface market. First financings represented 33% of deals in 2024, 22% in 2025, and 50% in year-to-date 2026. However, most first financings remain small unless the company has exceptional founder signal, platform ambition, or strategic investor backing.
North America remains the largest funding center, but Asia-Pacific is gaining real momentum. North America captured about 94% of disclosed capital in 2025, but only about 58% in year-to-date 2026, while Asia-Pacific jumped to about 41% on the back of BrainCo, StairMed, and Gestala.
The overall interpretation is that the brain-computer interface market is selectively maturing. A few companies are raising commercialization-scale and platform-scale rounds, while the broader market remains early, technically fragmented, and highly dependent on company-specific validation events.
Is more or less capital going into the brain-computer interface market?
More capital is going into the brain-computer interface market, but the increase is highly concentrated and should not be mistaken for broad-based funding health. The cleanest full-year comparison shows a major increase: disclosed funding rose from about $406M in 2024 to about $1.0B in 2025, which is roughly a 2.5x increase. The freshest comparison points in the same direction: year-to-date 2026 funding reached about $933M, compared with about $745M over the comparable period in 2025.
The capital increase is real, but the shape of the increase matters more than the headline number. In 2025, Neuralink alone accounted for about 65% of disclosed capital. In year-to-date 2026, the top three rounds, BrainCo at about $286M, Merge Labs at $250M, and Science Corporation at $230M, accounted for about 82% of disclosed capital.
That means the brain-computer interface market is not simply becoming easier for every company to finance. The market is becoming more capitalized around companies that investors see as platform-defining, strategically scarce, clinically meaningful, or technically differentiated.
The better reading is that capital availability is improving at the top of the brain-computer interface market. Smaller companies are still raising, but the lower half of deals captured only about 4% of year-to-date 2026 capital. So, yes, more capital is going into the market, but it is flowing disproportionately to a small set of perceived winners.
Is brain-computer interface funding activity driven by more deals or larger rounds?
Brain-computer interface funding activity is driven mainly by larger rounds, not by a dramatically higher number of deals. Full-year deal count was unchanged from 2024 to 2025, with 9 disclosed qualifying deals in each year, while total disclosed capital rose from about $406M to about $1.0B. That is the clearest signal that bigger rounds, not more rounds, powered the market expansion.
The round-size indicators confirm the same pattern. Average round size rose from about $45M in 2024 to about $111M in 2025, while median round size rose from $13M to $19M. The average moved much more than the median, which means outlier rounds pulled the market upward.
The freshest comparison is more balanced but still skewed. Year-to-date 2026 produced 10 deals versus 5 over the comparable period in 2025, so deal activity did improve. But year-to-date 2026 also had 5 deals of $50M or more, and the top three rounds captured more than 80% of capital.
The practical takeaway is that the brain-computer interface market is seeing both more deals and bigger rounds in the current period, but larger rounds still explain the dollar story. Deal count is improving, yet the capital curve remains dominated by a few outsized financings.
Is brain-computer interface capital moving toward later-stage or earlier-stage companies?
Brain-computer interface capital is still moving mostly toward later-stage companies, although year-to-date 2026 looks more mixed because one very large seed round distorts the early-stage picture. In 2025, Series B and later rounds captured about $898M, or nearly 90% of disclosed capital. Seed and Series A rounds captured only about $102M, or roughly 10%.
The full-year comparison with 2024 confirms that the later-stage bias is structural. In 2024, late-stage rounds captured about $352M, or nearly 87% of capital. In 2025, late-stage rounds captured nearly 90%. That means the biggest checks continued to go to companies that had already moved beyond initial formation.
Year-to-date 2026 looks less late-stage-heavy, with early-stage and Series A rounds capturing about $344M, or nearly 37% of capital, while late-stage and growth rounds captured about $589M, or about 63%. But Merge Labs accounted for $250M of the early-stage total. Without that single seed round, early-stage capital would look much less powerful.
The better interpretation is that the brain-computer interface market remains biased toward proven or strategically validated companies, but the market can make rare exceptions for early companies with exceptional platform narratives. The market has not become early-stage-led; it has become a market where late-stage clinical platforms dominate while a few early platform bets can raise unusually large rounds.
Is the brain-computer interface market maturing or still experimental?
The brain-computer interface market is maturing at the top while remaining experimental across the middle and bottom. The maturity signal is visible in the scale of the largest rounds: Neuralink raised $650M and Synchron raised $200M in 2025, while BrainCo, Science Corporation, StairMed, and Axoft all raised large rounds in year-to-date 2026. These are not small exploratory financings.
At the same time, the broader brain-computer interface market is not yet mature in the way a mainstream software or medical-device market would be mature. Deal counts remain low, with 9 qualifying deals in 2024, 9 in 2025, and 10 in year-to-date 2026. Long no-deal gaps also remain a recurring feature, including 174 days in 2024 and 154 days in 2025.
The technical landscape also remains experimental. Year-to-date 2026 financings covered non-invasive ultrasound, non-invasive BCI, retinal implants, visual cortex prosthetics, neuromuscular interfaces, stretchable electrodes, invasive wireless systems, and psychiatric brain stimulation. That range shows that the market has not converged on one winning architecture.
The honest interpretation is that the brain-computer interface market is selectively maturing. Leading companies can now raise platform-scale and commercialization-scale capital, but the overall market remains lumpy, technically plural, and dependent on clinical, regulatory, strategic, or interface proof points.
Are new startups still entering the brain-computer interface market?
Yes, new startups are still entering the brain-computer interface market, and year-to-date 2026 shows the strongest recent new-entrant signal. First financings represented 3 of 9 deals in 2024, 2 of 9 deals in 2025, and 5 of 10 deals in year-to-date 2026. By deal count, new-company formation is clearly alive.
The capital signal is more cautious. In 2024, first financings represented about 33% of deals but only about 5% of capital. In 2025, first financings represented about 22% of deals but only about 3% of capital. In year-to-date 2026, first financings represented 50% of deals and about 30% of capital, but Merge Labs accounted for most of that first-financing capital.
That distinction matters. Ordinary new brain-computer interface startups are still usually raising small proof-of-concept rounds. Exceptional new companies can raise much more if they combine a large platform thesis, strategic investor backing, strong founder signal, or a differentiated interface modality.
So, the brain-computer interface market is still open to new entrants, but the market is not broadly handing out large seed checks. New startups can enter, but large first financings are reserved for rare companies that look strategically important from day one.
Are more investors entering the brain-computer interface market?
More investors appear to be entering the brain-computer interface market in the current period, but the investor base is not yet showing deep repeat-investor behavior. Full-year 2024 had about 52 disclosed investor entries across 9 deals, while full-year 2025 had about 42 disclosed investor entries across 9 disclosed-amount deals. That full-year comparison does not show clear broadening.
The fresher comparison is more positive. The comparable period in 2025 had about 31 disclosed investor entries across 5 deals, while year-to-date 2026 had about 50 disclosed investor names or investor groups across 10 deals. That suggests investor participation has broadened, partly because the number of deals increased and partly because several large rounds had wide syndicates.
The quality of the investor mix has also changed. Year-to-date 2026 included OpenAI, Bain Capital, Lightspeed Venture Partners, Khosla Ventures, Y Combinator, IQT, Alibaba, Tencent, OrbiMed, Qiming Venture Partners, IDG Capital, Walden International, Ottobock, Hillhouse, and Gaorong. That is a broad mix of AI, strategic technology, defense-linked, China internet, medtech, deeptech, and growth investors.
However, more investors entering does not mean the brain-computer interface market has a settled specialist capital base. In 2024 and year-to-date 2026, no named investor appeared in more than one qualifying deal. Full-year 2025 had only one repeat top-investor signal, with Qatar Investment Authority participating in both Neuralink and Synchron.
Are top investors getting more or less active in the brain-computer interface market?
Top investors are getting more visible in the brain-computer interface market, but not consistently more active across multiple deals. The biggest rounds now include elite investors and strategic capital, but those investors are generally making company-specific bets rather than deploying repeatedly across the category.
In 2025, Neuralink attracted ARK Invest, Founders Fund, Lightspeed Venture Partners, Qatar Investment Authority, Sequoia Capital, and Thrive Capital, while Synchron attracted ARCH Ventures, Khosla Ventures, Bezos Expeditions, Qatar Investment Authority, and others. In year-to-date 2026, Science Corporation included Lightspeed, Khosla, Y Combinator, and IQT; Merge Labs included OpenAI and Bain Capital; StairMed included Alibaba, Tencent, OrbiMed, Qiming, and Lilly Asia; and BrainCo included IDG Capital and Walden International.
That is a strong visibility signal. Top investors are willing to show up when a brain-computer interface company has unusual clinical promise, platform scarcity, founder-market signal, strategic relevance, or commercialization potential.
But repeat activity remains weak. No disclosed investor appeared in more than one included year-to-date 2026 deal, and full-year 2025 had only Qatar Investment Authority as a clear repeat investor across more than one major round. So top investors are more visible, but they are not yet behaving like a dense specialist investor network.
Which brain-computer interface subcategories are gaining momentum?
The brain-computer interface subcategories gaining momentum are Non Invasive BCIs, Rehabilitation Interfaces, Clinical Neurotechnology, and selected Neuroprosthetics. The strongest change is visible when comparing 2025 with year-to-date 2026: 2025 was overwhelmingly implantable, while year-to-date 2026 spread capital across multiple interface architectures.
In 2025, Implantable BCIs captured about $925M, or 92.5% of disclosed capital. In year-to-date 2026, Rehabilitation Interfaces captured about $286M, or 31%; Non Invasive BCIs captured about $272M, or 29%; Clinical Neurotechnology captured about $230M, or 25%; and Implantable BCIs captured about $135M, or 15%.
The strongest signal is not just that non-invasive BCI raised more money. The stronger signal is that investors are now funding several routes to neural-interface scale: BrainCo in rehabilitation and prosthetics, Merge Labs and Gestala in non-invasive BCI, Science Corporation in visual restoration, and StairMed and Axoft in implantable systems.
Neuroprosthetics also gained visibility, though not yet large capital weight. Phantom Neuro raised $19M in 2025, while Blue Arbor and ReVision Implant together raised about $9M in year-to-date 2026. That points to a real but still capital-light neuroprosthetics lane.
Which brain-computer interface subcategories are losing momentum?
Implantable BCIs are losing relative momentum in year-to-date 2026, but not absolute relevance. In 2025, Implantable BCIs captured about 92.5% of disclosed capital and 55.6% of deals. In year-to-date 2026, Implantable BCIs captured only about 14.5% of capital, even though they still represented 30% of deals.
That means implantable BCI remains active by company count, but the biggest checks have shifted elsewhere so far in 2026. The shift should not be read as investor rejection of implants. It should be read as investors expanding the funding map beyond implants.
BCI Software Platforms also look weak as standalone pure plays. In 2024, Neurable’s $13M round created one clear BCI Software Platforms deal. In 2025 and year-to-date 2026, standalone BCI Software Platforms did not appear as a major disclosed pure-play category. Signal processing is still essential, but capital is flowing to software when it is embedded inside devices, implants, electrodes, wearables, or clinical systems.
Consumer Neurotech is also intermittent. Elemind raised $12M in 2024 and Neurable raised $35M in late 2025, but there was no qualifying Consumer Neurotech deal in year-to-date 2026. The category remains investable, but it is not currently driving the main BCI funding cycle.
Which regions are gaining momentum in the brain-computer interface market?
Asia-Pacific is the region gaining the clearest momentum in the brain-computer interface market, while North America remains the largest funding center. In full-year 2025, North America captured about 94% of disclosed capital, while Asia-Pacific captured about 5%. In year-to-date 2026, Asia-Pacific captured about 41% of disclosed capital.
This is a major change because Asia-Pacific did not simply add small experimental rounds. BrainCo raised about $286M, StairMed raised about $73M, and Gestala raised about $22M. These rounds gave Asia-Pacific about $381M of year-to-date 2026 capital.
North America still gained in absolute terms, with about $540M raised in year-to-date 2026 across Merge Labs, Science Corporation, Axoft, and Blue Arbor. But North America’s capital share fell from about 94% in 2025 to about 58% in year-to-date 2026 because Asia-Pacific strengthened materially.
Europe gained deal-count visibility but not capital momentum. Europe had 3 of 10 year-to-date 2026 deals, the same count as Asia-Pacific, but those European deals totaled only about $12M. Europe is active, but still undercapitalized.
Which regions are losing momentum in the brain-computer interface market?
North America is losing relative share in the brain-computer interface market, but not strategic importance. North America captured about 85% of capital in 2024, about 94% in 2025, and about 58% in year-to-date 2026. The share decline reflects Asia-Pacific’s acceleration, not a collapse in North American financing.
Europe is losing capital relevance relative to its company count. Europe captured about $51M in 2024, mostly from INBRAIN’s $50M round. Europe had no disclosed-amount qualifying deal in 2025, then returned with 3 deals in year-to-date 2026 but only about $12M of capital. That points to technical activity without scale funding.
The Middle East also lost company-formation visibility after brain.space’s $11M Series A in 2025. There were no qualifying Middle East company financings in year-to-date 2026. However, Middle East capital still matters indirectly through investors such as Qatar Investment Authority in major global rounds.
Latin America and Africa remain absent from the strict disclosed BCI financing evidence across 2024, 2025, and year-to-date 2026. That absence matters because the brain-computer interface market depends on specialized engineering talent, neurosurgical access, regulatory pathways, advanced manufacturing, and deep pools of high-risk capital.
Is the brain-computer interface market becoming more global or more regionally concentrated?
The brain-computer interface market is becoming more global by company geography, but capital remains concentrated around North America and Asia-Pacific. In 2024, North America captured about 85% of disclosed capital, Europe about 13%, and Asia-Pacific about 2%. In 2025, North America became even more dominant, with about 94% of capital. In year-to-date 2026, North America captured about 58%, Asia-Pacific about 41%, and Europe about 1%.
That year-to-date 2026 mix is meaningfully more global than the 2025 mix. Asia-Pacific became a major capital center because BrainCo, StairMed, and Gestala all raised meaningful rounds. Europe also contributed three deals, though the dollars remained small.
However, the brain-computer interface market is not globally balanced. The market is shifting from North America-dominated toward a North America-and-China axis. That is globalization, but it is not broad global diffusion.
The right interpretation is that the BCI funding map is becoming less one-region-dependent, while still excluding most regions from capital-scale participation. The market is more global than before, but the serious capital remains concentrated in a small number of advanced deeptech and medical-device ecosystems.
Is brain-computer interface capital moving toward proven winners or new opportunities?
Brain-computer interface capital is moving toward both proven winners and selected new opportunities, but proven or strategically credible companies still capture most of the money. In 2025, the answer was heavily tilted toward proven winners: follow-on rounds captured nearly all capital, and Series B or later rounds captured almost 90% of disclosed dollars.
Year-to-date 2026 is more balanced by deal count. First financings represented 5 of 10 deals and captured about 30% of capital. That is a much stronger new-opportunity signal than the comparable period in 2025, when first financings represented only 1 of 5 deals and about 2% of capital.
But the new-opportunity signal is selective, not broad. Merge Labs accounted for $250M of first-financing capital, which means most new companies still raised much smaller rounds. The largest follow-on companies, including BrainCo, Science Corporation, StairMed, Axoft, and Neurosoft, remained central to the capital story.
The better interpretation is that the brain-computer interface market still rewards proven winners, but the definition of “proven” is expanding. Clinical validation, platform optionality, strategic investor support, founder signal, and geopolitical relevance can all attract large checks before conventional commercialization maturity is fully visible.
Is the brain-computer interface market becoming winner-takes-most?
Yes, the brain-computer interface market is becoming winner-takes-most in capital allocation, even though the technology landscape remains diverse. In 2024, the top 3 deals captured about 87% of disclosed capital. In 2025, the top 3 captured about 90%. In year-to-date 2026, the top 3 captured about 82%.
The bottom-half share tells the same story. The bottom half of deals captured about 5% of capital in 2024, about 5% in 2025, and about 4% in year-to-date 2026. That means the market has grown, but the lower half has not captured a larger share of funding.
Still, the brain-computer interface market is not winner-takes-all technologically. Year-to-date 2026 capital went into Rehabilitation Interfaces, Non Invasive BCIs, Clinical Neurotechnology, Implantable BCIs, and Neuroprosthetics. The market has not picked one winning interface modality.
The precise framing is winner-takes-most, not winner-takes-all. A small number of companies capture most of the capital, but investors are still underwriting multiple technical routes to brain-computer interface adoption.
Is the next wave of brain-computer interface winners becoming visible?
Yes, the next wave of brain-computer interface winners is becoming visible, but visibility does not yet equal full validation. The companies with the strongest signals include Neuralink, Synchron, BrainCo, Science Corporation, StairMed, Axoft, and Merge Labs. These companies have attracted large rounds, strong investors, differentiated technical theses, or a combination of all three.
The next-wave signal is strongest where large capital meets a credible deployment path. Science Corporation’s $230M Series C points to visual restoration as a serious clinical BCI lane. BrainCo’s $286M financing points to China-scale rehabilitation and prosthetics commercialization. StairMed’s repeated large rounds point to China’s implantable BCI ambitions. Axoft’s $55M Series A points to soft implantable interfaces as a credible alternative architecture.
Merge Labs is a different kind of signal. Its $250M seed round makes it impossible to ignore, but the round reflects strategic narrative, founder signal, and platform optionality more than conventional clinical proof. Merge Labs should be evaluated differently from companies that already have human-use or clinical deployment evidence.
The next wave is visible, but still unresolved. The eventual winners will probably be companies that combine interface performance, deployment pathway, safety profile, regulatory strategy, manufacturing readiness, and strategic investor support.
Is the brain-computer interface funding landscape fragmenting or consolidating?
The brain-computer interface funding landscape is consolidating by capital but fragmenting by technical thesis and investor syndicate. Capital is consolidating because the top 3 deals captured more than 80% of disclosed capital in 2024, 2025, and year-to-date 2026. That is a clear concentration pattern.
The technical landscape is moving in the opposite direction. The market is funding invasive implants, endovascular systems, soft cortical electrodes, retinal implants, visual cortex prosthetics, ultrasound-based non-invasive interfaces, neurorehabilitation systems, neuromuscular prosthetic interfaces, and stretchable electrode platforms.
The investor landscape is also fragmented. No investor appeared in more than one qualifying year-to-date 2026 deal, and repeat investor activity was limited in 2025. Each major company is building a different syndicate around a different thesis: AI capital for Merge Labs, China strategic capital for BrainCo and StairMed, clinical and deeptech investors for Science and Axoft, and medtech strategic capital for Blue Arbor.
The best interpretation is that the brain-computer interface market has concentrated capital around a few highly credible experiments, while the underlying market remains technically and syndicate-fragmented. The market has not converged; it has only funded the most convincing paths more aggressively.
Where is investor attention shifting in the brain-computer interface market?
Investor attention in the brain-computer interface market is shifting from generic BCI ambition toward deployment credibility, platform optionality, and strategic control of neural-interface infrastructure. In 2024 and 2025, the biggest capital signal was implantable BCI, led by Blackrock Neurotech, Precision Neuroscience, Neuralink, Synchron, StairMed, and Subsense. That reflected belief in high-bandwidth interfaces and clinical restoration as the first capital-scale BCI lane.
Year-to-date 2026 shows a wider attention pattern. Investors funded BrainCo’s rehabilitation and prosthetics ecosystem, Merge Labs’ non-invasive human-AI interface thesis, Science Corporation’s visual restoration implant, StairMed’s China implantable BCI platform, Gestala’s ultrasound-based BCI, Axoft’s soft implantable interface, and Neurosoft’s stretchable electrode platform.
The clearest shift is toward companies that can own an interface layer rather than companies that simply build one device. BrainCo can be read as rehabilitation and prosthetics infrastructure. Merge Labs can be read as human-AI interface infrastructure. Science Corporation can be read as sensory restoration infrastructure. StairMed, Axoft, and Neurosoft can be read as access-layer infrastructure.
The brain-computer interface market is therefore shifting toward platform control. Investors are still interested in clinical outcomes, but the largest checks increasingly go to companies that can plausibly become standard interfaces between nervous systems, devices, AI systems, or restoration workflows.
INSIGHTS
The insights below come from reviewing publicly disclosed equity funding activity in the brain-computer interface market across full-year 2024, full-year 2025, and year-to-date 2026 through July 2026.
- The brain-computer interface market is growing by capital but not becoming broadly liquid. Funding rose from about $406M in 2024 to about $1.0B in 2025 and about $933M in year-to-date 2026, but deal count stayed low and capital remained concentrated in a few companies.
- The most reliable reading rule for the brain-computer interface market is to separate capital volume from market breadth. A year can look explosive because of one or two mega-rounds even if most companies are still raising small milestone financings.
- Full-year 2025 was structurally more concentrated than 2024 because total capital increased by roughly 2.5x while deal count did not increase. Round inflation, not startup proliferation, drove the apparent market expansion.
- Year-to-date 2026 looks healthier than 2025 by deal count, with 10 deals versus 5 over the comparable period in 2025. But the top 3 year-to-date 2026 deals still captured about 82% of capital, so the broader deal base has not eliminated concentration risk.
- The brain-computer interface market is becoming winner-takes-most in financing before it has become winner-takes-most in technology. Funding is concentrated, but the funded modalities remain diverse.
- Implantable BCI was the dominant funding thesis in 2025, but year-to-date 2026 shows a rotation toward a broader interface stack. Rehabilitation Interfaces, Non Invasive BCIs, and Clinical Neurotechnology all captured more year-to-date 2026 capital than Implantable BCIs.
- The decline in Implantable BCI capital share from about 92.5% in 2025 to about 14.5% in year-to-date 2026 should not be read as loss of confidence in implants. The better reading is that other BCI architectures finally received mega-round-scale validation.
- Non-invasive BCI gained credibility in year-to-date 2026 because investors funded it at platform scale, not just consumer-wearable scale. Merge Labs and Gestala together made Non Invasive BCIs one of the largest capital categories in the current period.
- The market’s largest rounds increasingly price optionality, not only current proof. Merge Labs’ $250M seed round shows that strategic narrative, founder signal, and AI adjacency can substitute for conventional clinical maturity.
- Clinical proof still matters most for durable credibility. Science Corporation, Neuralink, Synchron, StairMed, Axoft, and BrainCo all point to a market where human-use evidence, restoration use cases, or regulated deployment paths matter more than abstract decoding claims.
- The brain-computer interface market is no longer a pure healthcare market. The investor base now includes AI, sovereign, defense-linked, China internet, consumer technology, medtech, and deeptech investors.
- Strategic investors are more informative than generic financial investors in this market. Ottobock, OpenAI, Alibaba, Tencent, IQT, Qatar Investment Authority, and major medtech or AI-linked participants signal commercialization routes, industrial relevance, or strategic scarcity.
- Repeat investor activity remains surprisingly weak. Aside from Qatar Investment Authority appearing in both Neuralink and Synchron in 2025, there is little evidence that investors are systematically deploying across multiple BCI companies.
- North America remains the core funding geography, but year-to-date 2026 shows that Asia-Pacific is now a serious competitor. Asia-Pacific captured about 41% of year-to-date 2026 capital, driven by BrainCo, StairMed, and Gestala.
- China’s BCI funding momentum is especially important because it combines capital scale with strategic industrial participation. BrainCo and StairMed suggest that China is funding BCI as part of a broader robotics, rehabilitation, semiconductor, medical-device, and interface-infrastructure strategy.
- Europe is technically active but undercapitalized. Europe had 3 year-to-date 2026 deals but only about 1% of capital, which implies a prototype and early-clinical ecosystem rather than a scale-financing ecosystem.
- First financings show that new-company formation is real, especially in year-to-date 2026, but new startups remain economically secondary unless they have exceptional strategic positioning. Merge Labs accounted for most of the first-financing capital in the current period.
- Median round size is usually more informative than average round size in the brain-computer interface market. The average is repeatedly distorted by mega-rounds, while the median better reflects what a typical funded BCI company can raise.
- The market has a persistent barbell structure. Many companies raise small milestone rounds to advance proof points, while a small group raises $50M-plus or $100M-plus rounds to pursue platform scale.
- BCI Software Platforms look weak as standalone pure plays. Signal processing is essential, but capital is flowing to software when it is embedded inside proprietary devices, data systems, implants, electrodes, wearables, or clinical platforms.
- Visual restoration is emerging as a credible BCI application lane. Science Corporation’s $230M Series C and ReVision Implant’s cortical visual prosthesis financing suggest that sensory restoration may become one of the most investable clinical pathways.
- The market is moving from “can brain signals be decoded?” toward “can neural interfaces be deployed safely and repeatedly?” Large financings increasingly support clinical trials, commercialization, manufacturing, strategic deployment, and scalable interface architecture.
- A durable market inflection would require three signals that are not yet fully visible: more repeat investors, more mid-sized institutional rounds, and more companies progressing from early proof to follow-on financing. Until those appear, the brain-computer interface market should be described as high-conviction but still structurally fragile.
OUR METHODOLOGY TO BUILD THIS TRACKER
We built this brain-computer interface funding tracker by reviewing publicly disclosed equity rounds raised by pure-play BCI, neural-interface, neuroprosthetics, rehabilitation-interface, and clinical neurotechnology companies across full-year 2024, full-year 2025, and year-to-date 2026 through July 2026. A company counts as pure-play when more than 80% of its activity is dedicated to recording, interpreting, stimulating, or interfacing with neural signals to control devices, restore function, support rehabilitation, enable neuroprosthetics, or advance brain-signal-based clinical technology.
We applied four core filters. First, we only included equity rounds, so grants, debt, acquisitions, public-market transactions, and non-dilutive awards were excluded. Second, we only counted rounds of $300K or more. Third, we only kept companies that fit the strict brain-computer interface market scope, which means broader neurostimulation, neurodiagnostics, peripheral nerve stimulation, digital health, and generic medical-device companies were excluded unless the funded business was clearly built around BCI or neural-interface use cases. Fourth, every included round had to be supported by a direct company announcement, investor announcement, wire-service release, tier-1 media report, specialist industry source, or relevant regional publication.
Undisclosed-amount rounds are excluded from dollar-based metrics because including them would distort totals, averages, medians, category shares, geography shares, and concentration ratios. The tracker may still mention undisclosed or non-comparable financings qualitatively when they help explain market activity, but quantitative analysis is based only on disclosed-amount equity rounds that pass the market scope and source-quality filters.
The methodology intentionally uses a strict pure-play definition. Companies focused mainly on adjacent neuromodulation, diagnostics, peripheral stimulation, spinal stimulation, generic neurotechnology, or broader healthcare were excluded even when they were sometimes described as neurotech companies. This keeps the brain-computer interface market analysis focused on companies where neural interface, BCI, neuroprosthetic, rehabilitation-interface, or brain-signal technology is the core business rather than a secondary label.
Related blog posts
- The most heavily funded startups in the Brain-Computer interface market
- The highest-valued startups in the Brain-Computer interface market
- What does funding activity look like in the Brain-Computer interface market?
